...
首页> 外文期刊>Nature reviews. Clinical oncology >Patient-reported outcomes as end points and outcome indicators in solid tumours
【24h】

Patient-reported outcomes as end points and outcome indicators in solid tumours

机译:患者报告的结局为实体瘤的终点和结局指标

获取原文
获取原文并翻译 | 示例

摘要

Patient-reported outcome (PRO) measures, such as quality of life, have been associated with relevant clinical end points and are prognostic for survival outcomes in a variety of solid cancers in adults. In the past few years, PROs have garnered a greater influence as established and clinically relevant measures that could alter the current paradigm of practice-changing therapeutic advances, as it has been recognized that classic clinical end points do not accurately portray a full appreciation of the benefits, risks and costs of therapy. In this Review, we comprehensively assess the correlation of PROs with treatment response and survival, and explore tumour-related and patient-centric composite end points in patients with cancer participating in clinical trials. Comparisons or composite end points that consider tumour-related and PRO components might help health-care providers, patients with cancer and decision makers to better understand the total clinical benefit of therapeutic interventions.
机译:患者报告的结局(PRO)措施,例如生活质量,已与相关的临床终点相关联,并可预后各种成人实体癌的生存结局。在过去的几年中,由于已经认识到经典的临床终点并不能准确地反映出对临床治疗的全面了解,PRO作为已确立的临床相关措施已获得了更大的影响,这些措施可能会改变目前改变治疗实践的范例。好处,风险和治疗费用。在本综述中,我们全面评估了PRO与治疗反应和生存率的相关性,并探讨了参与临床试验的癌症患者的肿瘤相关和以患者为中心的复合终点。比较或综合考虑肿瘤相关成分和PRO成分的终点可能有助于医疗保健提供者,癌症患者和决策者更好地了解治疗干预的总体临床益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号